1/16
04:05 pm
xene
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
1/13
04:06 am
xene
Xenon Pharmaceuticals (NASDAQ:XENE) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Xenon Pharmaceuticals (NASDAQ:XENE) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
1/12
08:30 am
xene
Xenon Outlines Key Upcoming Milestones at the 2026 J.P. Morgan Healthcare Conference
Medium
Report
Xenon Outlines Key Upcoming Milestones at the 2026 J.P. Morgan Healthcare Conference
1/9
08:02 am
xene
Xenon Pharmaceuticals (NASDAQ:XENE) had its price target raised by analysts at JPMorgan Chase & Co. from $60.00 to $62.00. They now have an "overweight" rating on the stock.
Low
Report
Xenon Pharmaceuticals (NASDAQ:XENE) had its price target raised by analysts at JPMorgan Chase & Co. from $60.00 to $62.00. They now have an "overweight" rating on the stock.
1/5
09:28 am
xene
Xenon to Present at the 44th Annual J.P. Morgan Healthcare Conference [Canadian Business Journal (Canada)]
Medium
Report
Xenon to Present at the 44th Annual J.P. Morgan Healthcare Conference [Canadian Business Journal (Canada)]
1/5
08:41 am
xene
Xenon to Present at the 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
Medium
Report
Xenon to Present at the 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
1/5
08:30 am
xene
Xenon to Present at the 44th Annual J.P. Morgan Healthcare Conference
Low
Report
Xenon to Present at the 44th Annual J.P. Morgan Healthcare Conference
12/11
12:31 pm
xene
Xenon Pharmaceuticals (NASDAQ:XENE) had its price target raised by analysts at Wells Fargo & Company from $44.00 to $48.00. They now have an "overweight" rating on the stock.
Low
Report
Xenon Pharmaceuticals (NASDAQ:XENE) had its price target raised by analysts at Wells Fargo & Company from $44.00 to $48.00. They now have an "overweight" rating on the stock.
12/5
09:28 am
xene
Xenon Showcases New 48-Month Azetukalner OLE Study Data in Epilepsy at AES 2025 [Canadian Business Journal (Canada)]
Low
Report
Xenon Showcases New 48-Month Azetukalner OLE Study Data in Epilepsy at AES 2025 [Canadian Business Journal (Canada)]
12/5
09:00 am
xene
Xenon Showcases New 48-Month Azetukalner OLE Study Data in Epilepsy at AES 2025
Low
Report
Xenon Showcases New 48-Month Azetukalner OLE Study Data in Epilepsy at AES 2025
12/4
06:05 pm
xene
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
Low
Report
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
12/4
05:20 pm
xene
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12/3
09:28 am
xene
Xenon Announces Investor Webinar Highlighting Azetukalner and Epilepsy Data from AES 2025 [Canadian Business Journal (Canada)]
Low
Report
Xenon Announces Investor Webinar Highlighting Azetukalner and Epilepsy Data from AES 2025 [Canadian Business Journal (Canada)]
12/3
09:12 am
xene
Xenon Announces Investor Webinar Highlighting Azetukalner and Epilepsy Data from AES 2025 [Yahoo! Finance]
Low
Report
Xenon Announces Investor Webinar Highlighting Azetukalner and Epilepsy Data from AES 2025 [Yahoo! Finance]
12/3
08:30 am
xene
Xenon Announces Investor Webinar Highlighting Azetukalner and Epilepsy Data from AES 2025
Low
Report
Xenon Announces Investor Webinar Highlighting Azetukalner and Epilepsy Data from AES 2025
11/25
09:28 am
xene
Xenon to Present New Azetukalner OLE Study Data in Epilepsy at AES 2025 [Canadian Business Journal (Canada)]
Medium
Report
Xenon to Present New Azetukalner OLE Study Data in Epilepsy at AES 2025 [Canadian Business Journal (Canada)]
11/25
08:30 am
xene
Xenon to Present New Azetukalner OLE Study Data in Epilepsy at AES 2025
Medium
Report
Xenon to Present New Azetukalner OLE Study Data in Epilepsy at AES 2025
11/21
05:31 am
xene
Xenon Pharmaceuticals (NASDAQ:XENE) was upgraded by analysts at Chardan Capital to a "strong-buy" rating.
Low
Report
Xenon Pharmaceuticals (NASDAQ:XENE) was upgraded by analysts at Chardan Capital to a "strong-buy" rating.
11/18
11:04 am
xene
Xenon Pharmaceuticals (NASDAQ:XENE) had its price target raised by analysts at JPMorgan Chase & Co. from $57.00 to $60.00. They now have an "overweight" rating on the stock.
Low
Report
Xenon Pharmaceuticals (NASDAQ:XENE) had its price target raised by analysts at JPMorgan Chase & Co. from $57.00 to $60.00. They now have an "overweight" rating on the stock.
11/6
08:30 am
xene
Xenon to Present at Upcoming Investor Conferences
Low
Report
Xenon to Present at Upcoming Investor Conferences
11/4
12:09 pm
xene
Xenon Pharmaceuticals (NASDAQ:XENE) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.
Low
Report
Xenon Pharmaceuticals (NASDAQ:XENE) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.
11/4
11:54 am
xene
Xenon Pharmaceuticals (NASDAQ:XENE) had its price target raised by analysts at Royal Bank Of Canada from $55.00 to $58.00. They now have an "outperform" rating on the stock.
Low
Report
Xenon Pharmaceuticals (NASDAQ:XENE) had its price target raised by analysts at Royal Bank Of Canada from $55.00 to $58.00. They now have an "outperform" rating on the stock.
11/4
08:09 am
xene
Xenon Pharmaceuticals (NASDAQ:XENE) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $55.00 price target on the stock.
Low
Report
Xenon Pharmaceuticals (NASDAQ:XENE) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $55.00 price target on the stock.
11/4
08:08 am
xene
Xenon Pharmaceuticals (NASDAQ:XENE) had its "overweight" rating reaffirmed by analysts at Wells Fargo & Company.
Low
Report
Xenon Pharmaceuticals (NASDAQ:XENE) had its "overweight" rating reaffirmed by analysts at Wells Fargo & Company.
11/4
08:08 am
xene
Xenon Pharmaceuticals (NASDAQ:XENE) had its "overweight" rating reaffirmed by analysts at Wells Fargo & Company.
Low
Report
Xenon Pharmaceuticals (NASDAQ:XENE) had its "overweight" rating reaffirmed by analysts at Wells Fargo & Company.